Acquisition Overview - Herbalife has acquired personalized supplement company Bioniq for a total deal value of up to $150 million, with an initial purchase price of $55 million and contingent payments of $95 million based on future performance [1][4]. Company Background - Bioniq was founded in 2019 by former German basketball player Vadim Fedotov and commerce veteran James Hardy, focusing on making health measurable and accessible through personalized daily formulas [2]. - The company operates on a member-based model where users receive tailored health solutions based on a lifestyle and health needs quiz [2]. Investment and Growth - Notable investors in Bioniq include soccer star Cristiano Ronaldo, who invested an undisclosed amount after being a member since 2022, along with other investors such as Diogo Dalot, Porsche Ventures, Rock Internet, and HV Capital [3]. Strategic Vision - Herbalife's CEO, Stephan Gratziani, emphasized the importance of personalized and data-driven health solutions, stating that the combination of Bioniq's technology with Herbalife's global infrastructure positions the company to deliver personalized nutrition to millions [4]. Financial Performance - Herbalife's market valuation has increased to $1.5 billion, up from $876.8 million a year ago, reflecting significant growth in the nutritional sector [5].

Core Viewpoint - Herbalife Ltd. is set to enhance its personalized nutritional supplement capabilities through the planned acquisition of Bioniq, a UK-based company specializing in personalized supplements, which aligns with Herbalife's vision of becoming a technology-enabled health and wellness platform [1][2]. Company Overview - Herbalife Ltd. is a premier health and wellness company that has been providing nutrition products and business opportunities through independent distributors since 1980, operating in over 90 markets [10]. - Bioniq, founded in 2019, focuses on personalized supplements based on individual health data and has developed unique formulas for hundreds of thousands of users [12]. Acquisition Details - The acquisition involves a purchase price of $55 million, to be paid over five years, with an initial payment of $10 million at closing and up to $95 million in contingent payments based on future performance [7]. - The transaction is expected to close in the second quarter of 2026, pending regulatory approvals [7]. Strategic Implications - The acquisition of Bioniq will complement Herbalife's previous acquisitions of Pro2col and Link BioSciences, allowing for a broader range of personalized nutritional supplements and enhancing Herbalife's global manufacturing capabilities [3]. - Herbalife has also secured a call option to acquire Bioniq LAB, which focuses on small molecules and peptides, providing strategic flexibility for future opportunities [8]. Market Expansion - Bioniq's personalized nutritional supplements are anticipated to be available later this year through Herbalife's independent distributors in select countries in Europe and the United States, with plans for further market expansion [9].

Group 1 - Herbalife has renewed its partnership with the LA Galaxy Special Olympics Unified Team for the 2026 season, continuing its role as the Official Nutrition Partner for over 20 years [1] - The partnership provides Special Olympics athletes aged 16 to 25 access to high-quality resources, including nutrition education, elite training, and exclusive experiences [1] - A signing ceremony was held on March 9, 2026, where 24 athletes officially joined the team, receiving a pro-team experience including a stadium tour and personalized uniforms [1] Group 2 - The LA Galaxy Special Olympics Unified Team will participate in various scrimmages and games throughout the season, highlighting inclusivity and teamwork [1] - The initiative aligns with Herbalife's mission to promote health and wellness through balanced nutrition and active lifestyles [1] - The support for the Unified Team is facilitated by the Joint Community Partnership Fund, a collaboration between Herbalife and the LA Galaxy [1]

Market Overview - The Personalized Nutrition Market was valued at USD 15.80 billion in 2025 and is projected to reach USD 60.92 billion by 2035, growing at a CAGR of 15.04% from 2026 to 2035 [1][7]. Market Drivers - Rising awareness of preventive healthcare, increasing lifestyle-related chronic diseases, and growing demand for customized wellness solutions are key factors driving the market [2]. - Consumers are increasingly seeking individualized diet plans, DNA-based programs, nutrigenomics testing, and AI-powered supplement recommendations [2]. Regional Insights - The United States is the market leader, with an estimated worth of USD 5.85 billion in 2025 and a projected CAGR of 15.11%, reaching USD 22.27 billion by 2035 [4]. - North America held over 38.64% of the market share in 2025, attributed to high consumer literacy around preventive health and the advantages of DNA-based dietary programs [15]. - Asia Pacific is the fastest-growing segment with a CAGR of 17.43%, driven by increasing awareness of precision dietary solutions and government health initiatives [14]. Market Segmentation - By Product: Dietary supplements & nutraceuticals accounted for approximately 42.36% of revenue in 2025, while the digitized DNA segment is expected to grow at nearly 17.82% CAGR [9]. - By End-User: The direct-to-consumer segment held about 53.28% of the market share and is projected to grow at a CAGR of around 15.63% [10]. - By Measurement Method: Active measurement dominated with a 61.47% share in 2025, driven by real-time monitoring capabilities [11]. - By Form: Capsules held a leading share of 34.19% in 2025, while the powder segment is projected to grow at the highest CAGR of 16.54% [12]. - By Application: Standard supplements accounted for 48.73% of the market, with the disease-based segment expected to expand at a CAGR of 16.91% [13]. Major Players - Key players in the market include Nestlé S.A., Amway Corporation, Herbalife Nutrition Ltd., and Abbott Laboratories [16][20]. - Recent developments include Nestlé's expansion of its personalized nutrition portfolio with AI-powered tools and Amway's launch of a DNA-linked supplement platform [20].

Financial Data and Key Metrics Changes - In Q4 2025, net sales reached $1.3 billion, reflecting a year-over-year growth of 6.3% [6][18] - For the full year, net sales increased nearly 1% to just over $5 billion, with an adjusted EBITDA of $658 million and a margin of 13.1% [8][18] - The total leverage ratio improved to 2.8x, down from 3.9x at the end of 2023, indicating stronger financial health [5][33] Business Line Data and Key Metrics Changes - North America experienced a 19% increase in new distributors in Q4, marking its second consecutive quarter of double-digit growth [9] - Latin America achieved its seventh consecutive quarter of year-over-year growth, with reported net sales up 18% [26] - The Asia Pacific region saw a 5% increase in reported net sales, driven by approximately 9% volume growth [27] Market Data and Key Metrics Changes - India delivered its highest quarterly net sales in Q4, with a 15% year-over-year increase, attributed to a reduction in the goods and services tax [19][27] - North America sales declined by less than 1% year-over-year, consistent with prior expectations [27] - China reported a 4% decline in net sales year-over-year, primarily due to an 11% decrease in volume [28] Company Strategy and Development Direction - The company aims to be the world's premier health and wellness platform, focusing on innovation and digital engagement [5][11] - Plans include launching personalized nutritional supplements and enhancing the distributor experience through digital tools [12][15] - The partnership with Cristiano Ronaldo is expected to elevate brand visibility and expand market reach [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and ability to execute, highlighting a strong foundation for future growth [17][38] - The company anticipates net sales growth in all regions except China for 2026, with a focus on leveraging the GST benefits in India [43][46] - Adjusted EBITDA guidance for Q1 2026 is set between $155 million to $175 million, with full-year expectations of $670 million to $710 million [35] Other Important Information - The company has repaid $283 million of debt in 2025, contributing to a stronger balance sheet [8][33] - A presentation change was made to better align distributor-related compensation reporting, with no impact on prior period results [31] Q&A Session Summary Question: Guidance on sales for different geographic segments in 2026 - Management expects net sales growth in every region except China, which is anticipated to improve in 2027 [42][43] Question: Expectations for Pro2col sales contribution - Minimal top-line contribution is built into guidance, with more upside potential as the program is in beta phase [44][45] Question: Growth in energy, sports, and fitness product categories - This category has historically outpaced overall performance, with successful launches contributing to growth [51] Question: Expansion of nutrition club infrastructure - The Breakfast Budget Clubs model is gaining traction in the UK and is being introduced in other markets [53][54] Question: Distributor retention rates and training programs - Improved retention is attributed to various support programs, enhancing distributor education and strategy [55][56] Question: Contribution of new products to sales growth - Successful product launches, including MultiBurn and HL Skin, have significantly contributed to sales [61] Question: Plans for distributor events in 2026 - The company plans to increase the number of events, with costs expected to rise slightly more than sales [62][64] Question: Strategy for evolving product offerings and customer base - The company aims to attract a more sophisticated customer base while deepening engagement with existing customers [71][73] Question: Impact of GST changes in India on sales - The reduced GST is expected to provide a tailwind until it laps in late September 2026 [77][78] Question: Relationship between distributor growth and member growth - Both distributor and preferred member growth are important, with adjustments made to focus on preferred customers [83][86]

Financial Data and Key Metrics Changes - In Q4 2025, net sales reached $1.3 billion, reflecting a year-over-year growth of 6.3% [6][18] - For the full year 2025, net sales increased nearly 1% to just over $5 billion, with an adjusted EBITDA of $658 million and a margin of 13.1% [8][18] - The total leverage ratio improved to 2.8x from 3.9x at the end of 2023, indicating stronger cash generation [5][33] Business Line Data and Key Metrics Changes - North America experienced a 19% increase in new distributors in Q4, marking its second consecutive quarter of double-digit growth [9] - Latin America achieved its seventh consecutive quarter of year-over-year growth, with reported net sales up 18% [26] - The Asia Pacific region saw reported net sales increase by 5% year-over-year, driven by volume growth [27] Market Data and Key Metrics Changes - India delivered its highest quarterly net sales in Q4, with a 15% increase year-over-year, attributed to a reduction in the Goods and Services Tax [19][27] - North America sales declined slightly by less than 1% year-over-year, consistent with prior expectations [27] - China reported a 4% decline in net sales year-over-year, primarily due to an 11% decrease in volume [28] Company Strategy and Development Direction - The company aims to be the world's premier health and wellness platform, focusing on innovation and digital engagement [5][11] - Plans include launching personalized nutritional supplements and enhancing the distributor experience through the Pro2col technology [12][15] - The partnership with Cristiano Ronaldo is expected to elevate brand visibility and expand customer engagement [16][74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and ability to execute, highlighting a strong foundation for long-term growth [17][37] - The company anticipates net sales growth in all regions except China for 2026, with a focus on leveraging the GST benefits in India [43][46] - The adjusted effective tax rate is expected to be approximately 30% for 2026, aligning with 2025 [36] Other Important Information - The company repaid $283 million of debt in 2025, contributing to a stronger financial profile [8][33] - Adjusted net income for Q4 was $48 million, with an adjusted diluted EPS of $0.45 [22][23] - The company has implemented a strategic phased beta rollout for Pro2col, enhancing distributor engagement [12][13] Q&A Session Summary Question: Guidance on sales for different geographic segments in 2026 - Management expects net sales growth in every region except China, which is anticipated to be a 2027 event [43] Question: Expectations for Pro2col's sales contribution - Very little top-line contribution is built into the current guidance, with more upside than risk anticipated [44] Question: Contribution of product categories to sales growth - The energy, sports, and fitness category has outpaced overall company performance, with successful product launches contributing to growth [51] Question: Expansion of Nutrition Clubs in Europe - The Breakfast Budget Clubs model is gaining interest, with training programs being conducted to support distributors [53] Question: Retention rates of Sales Leaders - Improved retention is attributed to better education and support programs for distributors [55] Question: Future distributor events and spending - The company plans to increase the number of events, with costs expected to rise slightly more than sales [62][64] Question: Strategy for evolving product offerings and customer base - The company aims to attract a more sophisticated customer base while deepening engagement with existing customers [71][73]

Core Viewpoint - Herbalife Ltd. reported strong financial results for Q4 and the full year of 2025, indicating solid momentum with net sales growth and adjusted EBITDA exceeding guidance [1] Financial Performance - The company achieved net sales growth in both Q4 and the entire year of 2025 [1] - Adjusted EBITDA for the year was above the company's guidance, showcasing operational efficiency and profitability [1] Strategic Initiatives - Cristiano Ronaldo's investment in Pro2col is highlighted as a strategic move to enhance personalized nutrition and wellness on a global scale [1] - The collaboration aims to integrate science, data, AI, innovation, and community to improve health and performance for millions [1]

[Music] [Applause] As a young girl, I watched my mother struggle to control her health. Blood pressure that would leave her feverish at times. Diabetes that would leave her with dizzy spells.Clining cholesterol. headsplitting migraines. She was prescribed pill after pill, but sadly none of them worked.She passed away at 47. That's 2 years older than I am right now. As an adult, I watched my father struggle with his health.Sois that would itch through the night. Arthritis that would make it difficult to walk ...

Financial Data and Key Metrics Changes - The company has seen a stabilization in global net sales growth, with five out of the last seven quarters showing constant currency net sales growth [57] - North America experienced a significant turnaround, with July marking the first year-over-year volume growth since April 2021 [56][58] - The adjusted EBITDA margin improved from 11.3% in 2023 to 12.7% in the previous year, with expectations to exceed this in the current year [90] Business Line Data and Key Metrics Changes - The nutrition club model remains strong, with approximately 10,000 clubs in the U.S. and 4 million consumers participating in around 50 million transactions [64] - The company is focusing on converting nutrition club visitors into long-term customers who purchase products for home use [66] Market Data and Key Metrics Changes - The company operates in 95 markets, with India being the largest market where Herbalife is perceived as a premium brand [26] - The U.S. market is showing signs of recovery, with a focus on leveraging the existing distributor network to drive sales [58][66] Company Strategy and Development Direction - The company aims to transition into a digital-first health and wellness platform, similar to models like Airbnb and Uber, to better connect with customers and distributors [20][21] - Recent acquisitions, including ProveIt and Link BioSciences, are intended to enhance the company's digital capabilities and personalized nutrition offerings [36][38] Management's Comments on Operating Environment and Future Outlook - Management views the rise of GLP-1 medications as an opportunity to support customers in their weight loss journeys, regardless of their chosen path [70][71] - The company has a robust forecasting process and tight control over expenses, which has led to consistent guidance achievement [84][85] Other Important Information - The company is in the process of launching a health and wellness app that is expected to generate revenue and enhance customer engagement [48][49] - The app will facilitate incremental product sales and subscription revenue opportunities, although significant impacts are anticipated in 2026 rather than 2025 [55] Q&A Session Summary Question: How is the company managing guidance and revenue predictions? - The company has exceeded EBITDA guidance for six or seven consecutive quarters and maintains a robust forecasting process [84][85] Question: What is the company's stance on GLP-1 medications? - Management considers GLP-1 medications a friend, aiming to support customers regardless of their weight loss choices [70][71] Question: How does the company plan to leverage its distributor network? - The company is focused on converting nutrition club visitors into long-term customers and enhancing distributor engagement through new tools and technology [66][68]

Financial Data and Key Metrics Changes - Net sales for Q2 2025 were $1.3 billion, down 1.7% compared to 2024, but flat on a constant currency basis [7][24] - Adjusted EBITDA was $174 million, exceeding guidance, with an adjusted EBITDA margin of 13.8%, down 30 basis points year over year due to unfavorable currency impacts [24][27] - The company paid down $55 million in debt during the quarter, maintaining a total leverage ratio of slightly under three times as of June 30 [27][28] Business Line Data and Key Metrics Changes - Product innovation included the launch of Multi Burn, a non-pharmaceutical weight loss supplement, and the introduction of a healthy lifespan product [6][19] - Distributor growth initiatives led to strong engagement, with nearly 38,000 attendees at training events globally [9][10] - New distributor growth was flat year over year, but four out of five regions saw increases, with Latin America leading at 16% growth [9] Market Data and Key Metrics Changes - In North America, net sales were down 4%, primarily due to a 6% decline in year-over-year volumes, but July marked the first month of year-over-year volume growth since April 2021 [33][8] - Latin America reported a strong performance with constant currency net sales up 9%, despite reported net sales being down 1% [31] - EMEA net sales were flat on a reported basis, while Asia Pacific saw a 2% decline in reported net sales [32] Company Strategy and Development Direction - The company aims to transform into a data-driven wellness platform, integrating technology and personalized solutions to meet evolving consumer needs [4][5] - The acquisition of Link Biosciences is expected to enhance personalized supplement formulations, providing a competitive advantage [21] - The company is focused on expanding its product offerings and enhancing distributor engagement through digital tools and AI [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and noted signs of accelerating momentum in sales [5][8] - The outlook for Q3 includes projected net sales growth of 0.5% to 4.5% year over year, with adjusted EBITDA expected to be between $150 million and $160 million [38][39] - The company has raised and narrowed its full-year net sales guidance range to down 1% to up 3% year over year [39][40] Other Important Information - The company is integrating the Protocol app, which aims to enhance distributor-customer connections and provide personalized health insights [11][12] - The launch of the Protocol app is expected to create new monetization opportunities and attract a new customer segment [48][63] - The company plans to expand the Protocol platform globally, with regulatory assessments underway for key markets [68] Q&A Session Summary Question: What are the monetization strategies for the Protocol app? - Management indicated that the app will serve as a tool for distributors to enhance customer engagement and will have options for both product and app subscriptions [48][63] Question: How does the company view pricing in relation to competitors? - The company plans to take pricing in line with market conditions and has not seen significant pressure from competitors [56][58] Question: What are the plans for high-cost debt management? - The company is considering refinancing options for high-cost debt as market conditions improve [69]